Evaluation of the CooperVision Stenfilcon A Soft Contact Lens for Daily Wear When Compared to the ClearSight 1 Day (Ocufilcon B) Soft Contact Lens

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Coopervision, Inc.
ClinicalTrials.gov Identifier:
NCT01354223
First received: January 10, 2011
Last updated: October 12, 2012
Last verified: October 2012
  Purpose

This study seeks to evaluate a new daily disposable contact lens compared to an existing daily disposable contact lens.


Condition Intervention Phase
Myopia
Device: stenfilcon A contact lens
Device: ocufilcon B contact lens
Phase 0

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the CooperVision Stenfilcon A Soft Contact Lens for Daily Wear When Compared to the CooperVision Ocufilcon B Soft Contact Lens

Resource links provided by NLM:


Further study details as provided by Coopervision, Inc.:

Primary Outcome Measures:
  • Primary Safety Endpoint: comparison of objective findings, including slit lamp findings and adverse events reported as associated with stenfilcon A contact lenses with those same findings reported as associated with ocufilcon B contact lenses. [ Time Frame: Three months ] [ Designated as safety issue: Yes ]
    The primary safety endpoint in this evaluation will be a comparison of the objective findings, including slit lamp findings and adverse events reported as associated with the stenfilcon A contact lenses with those same findings reported as associated with the ocufilcon B contact lenses. The working hypothesis states that the findings will be substantially equivalent between the stenfilcon A and the ocufilcon B contact lenses.

  • Primary Efficacy Endpoint: will be a comparison of the lens visual acuities reported as associated with stenfilcon A contact lenses with lens visual acuities reported as associated with ocufilcon B contact lenses [ Time Frame: Three months ] [ Designated as safety issue: No ]
    The primary efficacy endpoint in this evaluation will be a comparison of the lens visual acuities reported as associated with the stenfilcon A contact lenses with the lens visual acuities reported as associated with the ocufilcon B contact lenses. The working hypothesis states that the lens visual acuity results will be substantially equivalent between the stenfilcon A and the ocufilcon B contact lenses.


Secondary Outcome Measures:
  • Secondary Efficacy Endpoint: will be a comparison of the lens average wearing times and subject comfort [ Time Frame: Three months ] [ Designated as safety issue: No ]
    The secondary efficacy endpoint in this evaluation will be a comparison of the lens average wearing times and subject comfort. The working hypothesis states that the lens average wearing times and subject comfort results will be substantially equivalent between the stenfilcon A and the ocufilcon B contact lenses.


Enrollment: 90
Study Start Date: October 2010
Study Completion Date: April 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: stenfilcon A Device: stenfilcon A contact lens
Daily disposable contact lens worn in a daily wear, daily disposable mode
Device: ocufilcon B contact lens
Daily disposable contact lens worn in a daily wear, daily disposable mode

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Prior to being considered eligible to participate in this study, each subject MUST:

  • Be at least 18 years of age as of the date of evaluation for the study.
  • Have:

    • Read the Informed Consent
    • been given an explanation of the Informed Consent
    • indicated understanding of the Informed Consent
    • signed the Informed Consent document.
  • Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
  • Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses on a daily basis for at least 8 hours per day for at least one month prior to participation in the study.
  • Possess wearable and visually functional eyeglasses.
  • Be in good general health, based on his/her knowledge.
  • Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 1.00 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.
  • Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
  • Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye.

Exclusion Criteria:

Subjects may not be enrolled in this study if any of the following apply: The subject is/has:

  • Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
  • Poor personal hygiene.
  • Any active participation in another clinical trial within 30 days prior to this study.
  • Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next 3 months.
  • A member, relative or household member of the investigator or of the investigational office staff.
  • Has a known sensitivity to ingredients used in the over the counter contact lens lubricants approved for use in the study.
  • Previous refractive surgery; or current or previous orthokeratology treatment.
  • Is aphakic or psuedophakic.
  • Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes.
  • The need for topical ocular medications or any medication which might interfere with contact lens wear or which would require the lenses to be removed during the day.
  • The presence of clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures.
  • A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections.
  • A history of papillary conjunctivitis that has interfered with contact lens wear.
  • Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

    • Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > Grade 2
    • Pterygium
    • Corneal scars within the visual axis
    • Neovascularization or ghost vessels > 1.0 mm in from the limbus
    • Giant papillary conjunctivitis (GPC) of > Grade 2
    • Anterior uveitis or iritis
    • Sebborrheic eczema, sebborrheic conjunctivitis or blepharitis

To be eligible to be randomized for study product a subject must have ALL of the Inclusion Criteria and have NONE of the exclusion criteria present.

To be eligible for lens dispensing (either Test or Control), the subject's study lens contact lens visual acuity must be equal to or better than 20/30 in each eye.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01354223

Sponsors and Collaborators
Coopervision, Inc.
Investigators
Principal Investigator: Stephen Byrnes, OD
Principal Investigator: Lee Rigel, OD
Principal Investigator: Mary Jo Stiegemeier, OD
Principal Investigator: Peter Van Hoven, OD
Principal Investigator: Eric White, OD
  More Information

No publications provided

Responsible Party: Coopervision, Inc.
ClinicalTrials.gov Identifier: NCT01354223     History of Changes
Other Study ID Numbers: FC100239
Study First Received: January 10, 2011
Last Updated: October 12, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Coopervision, Inc.:
silicone hydrogel contact lens
SHCL
stenfilcon A
ocufilcon B
daily disposable
substantial equivalence
CooperVision ClearSight™ 1 Day SCL

Additional relevant MeSH terms:
Myopia
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on May 21, 2013